Document is current

Article History

Received: 22 November 2023

Accepted: 9 July 2024

First Online: 17 July 2024

Competing interests

: J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. She is a scientific advisory board member of Vertex Pharmaceuticals, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Algen Biotechnologies, Felix Biosciences, The Column Group and Inari. J.A.D. is Chief Science Advisor to Sixth Street, a Director at Johnson & Johnson, Altos and Tempus, and has research projects sponsored by Apple Tree Partners and Roche. The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is listed as an inventor. J.H.E. is a paid advisor to and receives sponsored research funding from Multiply Labs. He serves on its scientific advisory board and holds equity in the company. He is a paid advisor to and serves on the scientific advisory board of Shennon Biotechnologies and holds equity in the company. He receives sponsored research funding from Lonza, for the development of cellular therapy manufacturing devices. His research group received funding from Arsenal Bio. He is named as an inventor on patent application for CRISPR-based gene editing (WO2021183850A1). F.D.U. is a paid advisor to and holds equity in Tune Therapeutics and Cimeio Therapeutics, is a paid advisor to Ionis Pharmaceuticals, a paid consultant to Vertex Pharmaceuticals and receives salary support from Danaher. R.C.W. is a co-founder of EditPep. The other authors declare no competing interests.